Skip to main content
S&P 5007,592.40-0.58%DOW52,022.21-0.68%NASDAQ26,091.78-0.62%BTC$77,165.00-1.57%ETH$2,463.62-0.62%GOLD$4,372.10-1.99%OIL$102.07+6.27%
Smart Investors Daily
EV

NASDAQ · EVO

Evotec SE

Healthcare · Drug Manufacturers - Specialty & Generic

$1.81

Down-$0.04 (-2.21%)

Updated Sep 10, 2026, 4:20 PM

SID Score

3.1/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.08B
P/E ratio
-6.02
Dividend yield
0.00%
52-week range
$1.80 – $3.41
Volume
43.75K
Avg. volume
69.26K

Price performance

EVO price history

1M range · 20 trading sessions · Daily adjusted prices

EVO closed at $1.81 after 20 trading sessions, down 17.35% for the selected period.

Last close
$1.81
Period change
-17.35%
Period low
$1.80
Period high
$2.19
Daily close
View OHLC price history
EVO OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 9, 2026$1.83$1.83$1.805$1.8143.75K
Sep 8, 2026$1.83$1.83$1.80$1.8264.21K
Sep 4, 2026$1.86$1.86$1.8389$1.86121.91K
Sep 3, 2026$1.95$1.95$1.89$1.9094.28K
Sep 2, 2026$1.88$1.93$1.88$1.9048.22K
Sep 1, 2026$1.85$1.855$1.80$1.8038.41K
Aug 31, 2026$1.88$1.89$1.86$1.8865.94K
Aug 28, 2026$1.95$1.95$1.905$1.9128.22K
Aug 27, 2026$1.95$1.97$1.95$1.9731.28K
Aug 26, 2026$1.95$1.955$1.93$1.9531.08K
Aug 25, 2026$1.88$1.90$1.87$1.8925.34K
Aug 24, 2026$1.92$1.92$1.89$1.8922.65K
Aug 21, 2026$1.9191$1.95$1.915$1.9340.87K
Aug 20, 2026$1.95$1.96$1.915$1.9679.22K
Aug 19, 2026$1.90$1.98$1.90$1.9834.91K
Aug 18, 2026$1.93$1.94$1.89$1.9121.86K
Aug 17, 2026$1.938$1.96$1.9246$1.9630.21K
Aug 14, 2026$1.97$1.98$1.94$1.9641.96K
Aug 13, 2026$2.02$2.03$1.99$2.0228.46K
Aug 12, 2026$2.11$2.20$2.0906$2.1949.39K

Latest EVO news

The latest Smart Investors Daily articles mentioning EVO.

Stock researchCompany · Overview

EVO research

Overview

Company profile and research snapshot.

Company profile

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$7.00
Implied upside
—
Analysts
—
EVO recent ratings
DateFirmRatingTarget
Jun 29, 2026TD COWENBuy—
Jun 28, 2026PORTZAMPARC BNP PARIBASBuy—
May 17, 2026BERENBERGBuy—
May 6, 2026EQUI.TSNeutral—
Feb 4, 2026BERENBERGBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 2, 2026

Evotec and Plectonic Enter Research Collaboration to Explore New Generation of T-Cell-Engaging Approaches for Solid Tumors

Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) and Plectonic Biotech today announced a research collaboration to explore a novel immunotherapy approach for solid tumors. The collaboration addresses key challenges that have so far limited the successful application of traditional T cell engager therapies in solid tumors by combining Plectonic's programmable LOGIBODY® technology with Evotec's proprietary BiTco platform.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By